Juan F Masa1,2, Jaime Corral1,2, Maria L Alonso2,3, Estrella Ordax2,3, Maria F Troncoso2,4, Monica Gonzalez5, Soledad Lopez-Martínez6, Jose M Marin2,7, Sergi Marti2,8, Trinidad Díaz-Cambriles2,9, Eusebi Chiner10, Felipe Aizpuru11,12, Carlos Egea2,13. 1. 1 San Pedro de Alcantara Hospital, Caceres, Spain. 2. 2 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain. 3. 3 University Hospital, Burgos, Spain. 4. 4 IIS Fundacion Jimenez Diaz, Madrid, Spain. 5. 5 Valdecilla Hospital, Santander, Spain. 6. 6 Gregorio Marañon Hospital, Madrid, Spain. 7. 7 Miguel Servet Hospital, Zaragoza, Spain. 8. 8 Vall d'Hebron Hospital, Barcelona, Spain. 9. 9 12 de Octubre Hospital, Madrid, Spain. 10. 10 San Juan Hospital, Alicante, Spain. 11. 11 Araba Health Research Unit, Osakidetza, Alava Hospital, Álava, Spain. 12. 12 Department of Medicine of Basque Country University, Álava, Spain; and. 13. 13 Sleep Unit, Respiratory Department, Alava University Hospital IRB, Álava, Spain.
Abstract
RATIONALE: The incidence of obesity hypoventilation syndrome (OHS) may be increasing in parallel with the present obesity epidemic. Despite extensive noninvasive ventilation (NIV) and continuous positive airway pressure (CPAP) use in patients with OHS, information regarding efficacy is limited. OBJECTIVES: We performed a large, multicenter randomized controlled study to determine the comparative efficacy of NIV, CPAP, and lifestyle modification (control group) using daytime PaCO2 as the main outcome measure. METHODS:Sequentially screened patients with OHS with severe sleep apnea were randomized into the above-mentioned groups for a 2-month follow up. Arterial blood gas parameters, clinical symptoms, health-related quality-of-life assessments, polysomnography, spirometry, 6-minute-walk distance, dropouts, compliance, and side effects were evaluated. Statistical analysis was performed using intention-to-treat analysis, although adjustments for CPAP and NIV compliance were also analyzed. MEASUREMENTS AND MAIN RESULTS: In total, 351 patients were selected, and 221 were randomized. NIV yielded the greatest improvement in PaCO2 and bicarbonate, with significant differences relative to the control group but not relative to the CPAP group. In the CPAP group, PaCO2 improvement was significantly different than in the control group only after CPAP compliance adjustment. Additionally, clinical symptoms and polysomnographic parameters improved similarly with NIV and CPAP relative to the control. However, some health-related quality-of-life assessments, the spirometry, and 6-minute-walk distance results improved more with NIV than with CPAP. Dropouts were similar between groups, and compliance and secondary effects were similar between NIV and CPAP. CONCLUSIONS: NIV and CPAP were more effective than lifestyle modification in improving clinical symptoms and polysomnographic parameters, although NIV yielded better respiratory functional improvements than did CPAP. Long-term studies must demonstrate whether this functional improvement has relevant implications. Clinical trial registered with www.clinicaltrials.gov (NCT01405976).
RCT Entities:
RATIONALE: The incidence of obesity hypoventilation syndrome (OHS) may be increasing in parallel with the present obesity epidemic. Despite extensive noninvasive ventilation (NIV) and continuous positive airway pressure (CPAP) use in patients with OHS, information regarding efficacy is limited. OBJECTIVES: We performed a large, multicenter randomized controlled study to determine the comparative efficacy of NIV, CPAP, and lifestyle modification (control group) using daytime PaCO2 as the main outcome measure. METHODS: Sequentially screened patients with OHS with severe sleep apnea were randomized into the above-mentioned groups for a 2-month follow up. Arterial blood gas parameters, clinical symptoms, health-related quality-of-life assessments, polysomnography, spirometry, 6-minute-walk distance, dropouts, compliance, and side effects were evaluated. Statistical analysis was performed using intention-to-treat analysis, although adjustments for CPAP and NIV compliance were also analyzed. MEASUREMENTS AND MAIN RESULTS: In total, 351 patients were selected, and 221 were randomized. NIV yielded the greatest improvement in PaCO2 and bicarbonate, with significant differences relative to the control group but not relative to the CPAP group. In the CPAP group, PaCO2 improvement was significantly different than in the control group only after CPAP compliance adjustment. Additionally, clinical symptoms and polysomnographic parameters improved similarly with NIV and CPAP relative to the control. However, some health-related quality-of-life assessments, the spirometry, and 6-minute-walk distance results improved more with NIV than with CPAP. Dropouts were similar between groups, and compliance and secondary effects were similar between NIV and CPAP. CONCLUSIONS: NIV and CPAP were more effective than lifestyle modification in improving clinical symptoms and polysomnographic parameters, although NIV yielded better respiratory functional improvements than did CPAP. Long-term studies must demonstrate whether this functional improvement has relevant implications. Clinical trial registered with www.clinicaltrials.gov (NCT01405976).
Authors: W Kinnear; L Watson; P Smith; L Johnson; S Burrows; J Colt; M Sovani; A Khanna Journal: Chron Respir Dis Date: 2016-12-06 Impact factor: 2.444
Authors: Aljohara S Almeneessier; Samar Z Nashwan; Mostafa Q Al-Shamiri; Seithikurippu R Pandi-Perumal; Ahmed S BaHammam Journal: J Thorac Dis Date: 2017-03 Impact factor: 2.895
Authors: Juan F Masa; Jaime Corral; Auxiliadora Romero; Candela Caballero; Joaquin Terán-Santos; Maria L Alonso-Álvarez; Teresa Gomez-Garcia; Mónica González; Soledad López-Martínez; Pilar De Lucas; José M Marin; Sergi Marti; Trinidad Díaz-Cambriles; Eusebi Chiner; Miguel Merchan; Carlos Egea; Ana Obeso; Babak Mokhlesi Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062
Authors: Sherri L Katz; Joanna E MacLean; Nicholas Barrowman; Lynda Hoey; Linda Horwood; Glenda N Bendiak; Valerie G Kirk; Stasia Hadjiyannakis; Laurent Legault; Bethany J Foster; Evelyn Constantin Journal: J Clin Sleep Med Date: 2018-03-15 Impact factor: 4.062
Authors: Jason R Carter; Ida T Fonkoue; Daniela Grimaldi; Leila Emami; David Gozal; Colin E Sullivan; Babak Mokhlesi Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-01-27 Impact factor: 3.619